Rigel Pharma (RIGL) Tops Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $42.56 +5.74%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
EPAC, SAR, KRUS, More
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $26.1 million versus the consensus estimate of $23.55 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
